Teva invests EUR 35 mln in new drug Bulgarian plant

Israel-based Teva Pharmaceutical Industries will invest approximately EUR 35 million in the construction of a new drug production plant in Dupnitsa, southwestern Bulgaria.

Тhe new plant will complement Teva's existing manufacturing facility in Dupnitsa, significantly increasing production capacity by over 800 million tablets/capsules per year and creating about 70 new jobs, according to the company’s statement.

Production at the new plant is expected to begin at the end of 2023 after the facility receives approval from the respective regulatory bodies.

Teva has an investment programme for the European market in the next five years that also includes a new global centre for the production of biopharmaceuticals in Ulm, Germany and an increase of production capacity in Zaragoza, Spain.